You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
INDICATIONS AS AT 30 APRIL 2004: In Patients with Hypertension. MINIPRESS (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. Renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. MINIPRESS can be used with safety in hypertensive patients with impaired renal function. In Patients with Congestive Heart Failure. MINIPRESS is indicated in the treatment of severe refractory congestive heart failure. MINIPRESS may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. In Patients with Raynaud's Phenomenon and Raynaud's Disease. MINIPRESS is indicated in the treatment of Raynaud's Phenomenon and Raynaud's disease. Benign Prostatic Hyperplasia. MINIPRESS is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 30 APRIL 2004: In Patients with Hypertension. MINIPRESS (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. Renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. MINIPRESS can be used with safety in hypertensive patients with impaired renal function. In Patients with Congestive Heart Failure. MINIPRESS is indicated in the treatment of severe refractory congestive heart failure. MINIPRESS may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. In Patients with Raynaud's Phenomenon and Raynaud's Disease. MINIPRESS is indicated in the treatment of Raynaud's Phenomenon and Raynaud's disease. Benign Prostatic Hyperplasia. MINIPRESS is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 31 APRIL 2004: In Patients with Hypertension. MINIPRESS (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. Renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. MINIPRESS can be used with safety in hypertensive patients with impaired renal function. In Patients with Congestive Heart Failure. MINIPRESS is indicated in the treatment of severe refractory congestive heart failure. MINIPRESS may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. In Patients with Raynaud's Phenomenon and Raynaud's Disease. MINIPRESS is indicated in the treatment of Raynaud's Phenomenon and Raynaud's disease. Benign Prostatic Hyperplasia. MINIPRESS is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
